Literature DB >> 29700119

Assembly of human C-terminal binding protein (CtBP) into tetramers.

Andrew G Bellesis1,2, Anne M Jecrois1, Janelle A Hayes1, Celia A Schiffer1, William E Royer3.   

Abstract

C-terminal binding protein 1 (CtBP1) and CtBP2 are transcriptional coregulators that repress numerous cellular processes, such as apoptosis, by binding transcription factors and recruiting chromatin-remodeling enzymes to gene promoters. The NAD(H)-linked oligomerization of human CtBP is coupled to its co-transcriptional activity, which is implicated in cancer progression. However, the biologically relevant level of CtBP assembly has not been firmly established; nor has the stereochemical arrangement of the subunits above that of a dimer. Here, multi-angle light scattering (MALS) data established the NAD+- and NADH-dependent assembly of CtBP1 and CtBP2 into tetramers. An examination of subunit interactions within CtBP1 and CtBP2 crystal lattices revealed that both share a very similar tetrameric arrangement resulting from assembly of two dimeric pairs, with specific interactions probably being sensitive to NAD(H) binding. Creating a series of mutants of both CtBP1 and CtBP2, we tested the hypothesis that the crystallographically observed interdimer pairing stabilizes the solution tetramer. MALS data confirmed that these mutants disrupt both CtBP1 and CtBP2 tetramers, with the dimer generally remaining intact, providing the first stereochemical models for tetrameric assemblies of CtBP1 and CtBP2. The crystal structure of a subtle destabilizing mutant suggested that small structural perturbations of the hinge region linking the substrate- and NAD-binding domains are sufficient to weaken the CtBP1 tetramer. These results strongly suggest that the tetramer is important in CtBP function, and the series of CtBP mutants reported here can be used to investigate the physiological role of the tetramer.
© 2018 Bellesis et al.

Entities:  

Keywords:  CtBP; MALS; NAD(H); cancer; cancer target; crystallography; dehydrogenase; structural biology; tetrameric assembly; transcription coregulator

Mesh:

Substances:

Year:  2018        PMID: 29700119      PMCID: PMC5995525          DOI: 10.1074/jbc.RA118.002514

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.

Authors:  Brendan J Hilbert; Steven R Grossman; Celia A Schiffer; William E Royer
Journal:  FEBS Lett       Date:  2014-03-19       Impact factor: 4.124

2.  C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs.

Authors:  Madeleine Grooteclaes; Quinn Deveraux; Jeffrey Hildebrand; Qinghong Zhang; Richard H Goodman; Steven M Frisch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

3.  Redox sensor CtBP mediates hypoxia-induced tumor cell migration.

Authors:  Qinghong Zhang; Su-Yan Wang; Amanda C Nottke; Jonathan V Rocheleau; David W Piston; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-01       Impact factor: 11.205

4.  Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5.

Authors:  Weijun Chen; Suvana S Lam; Hema Srinath; Zhaozhao Jiang; John J Correia; Celia A Schiffer; Katherine A Fitzgerald; Kai Lin; William E Royer
Journal:  Nat Struct Mol Biol       Date:  2008-10-05       Impact factor: 15.369

Review 5.  The transcriptional corepressor CtBP: a foe of multiple tumor suppressors.

Authors:  G Chinnadurai
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

6.  The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain.

Authors:  Sharon S C Thio; Joseph V Bonventre; Stephen I-Hong Hsu
Journal:  Nucleic Acids Res       Date:  2004-03-22       Impact factor: 16.971

Review 7.  C-terminal binding proteins: emerging roles in cell survival and tumorigenesis.

Authors:  L M Bergman; J P Blaydes
Journal:  Apoptosis       Date:  2006-06       Impact factor: 4.677

8.  CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Xin Zheng; Tao Song; Changwei Dou; Yuli Jia; Qingguang Liu
Journal:  Oncotarget       Date:  2015-02-28

9.  Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.

Authors:  E T Sumner; A T Chawla; A D Cororaton; J E Koblinski; R C Kovi; I M Love; B B Szomju; S Korwar; K C Ellis; S R Grossman
Journal:  Oncogene       Date:  2017-04-17       Impact factor: 9.867

10.  NEURL4 regulates the transcriptional activity of tumor suppressor protein p53 by modulating its oligomerization.

Authors:  Monica Cubillos-Rojas; Taiane Schneider; Ramon Bartrons; Francesc Ventura; Jose Luis Rosa
Journal:  Oncotarget       Date:  2017-06-27
View more
  18 in total

1.  A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity.

Authors:  David B Beck; T Subramanian; S Vijayalingam; Uthayashankar R Ezekiel; Sandra Donkervoort; Michele L Yang; Holly A Dubbs; Xilma R Ortiz-Gonzalez; Shenela Lakhani; Devorah Segal; Margaret Au; John M Graham; Sumit Verma; Darrel Waggoner; Marwan Shinawi; Carsten G Bönnemann; Wendy K Chung; G Chinnadurai
Journal:  Neurogenetics       Date:  2019-04-30       Impact factor: 2.660

2.  Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.

Authors:  M Michael Dcona; Priyadarshan K Damle; Francisco Zarate-Perez; Benjamin L Morris; Zaid Nawaz; Michael J Dennis; Xiaoyan Deng; Sudha Korwar; Sahib J Singh; Keith C Ellis; William E Royer; Dipankar Bandyopadhyay; Carlos Escalante; Steven R Grossman
Journal:  Mol Pharmacol       Date:  2019-04-29       Impact factor: 4.436

3.  C-terminal of E1A binding protein 2 promotes the malignancy of osteosarcoma cells via JAK1/Stat3 signaling.

Authors:  Pengyun Wang; Benfeng Yu; Chengyan Wang; Shu Zhou
Journal:  J Cell Commun Signal       Date:  2019-06-19       Impact factor: 5.782

4.  NAD+ promotes assembly of the active tetramer of aldehyde dehydrogenase 7A1.

Authors:  David A Korasick; Tommi A White; Srinivas Chakravarthy; John J Tanner
Journal:  FEBS Lett       Date:  2018-09-18       Impact factor: 4.124

5.  Tête-à-tête with CtBP dimers.

Authors:  Ana-Maria Raicu; Kalynn M Bird; David N Arnosti
Journal:  Structure       Date:  2021-04-01       Impact factor: 5.006

6.  Cryo-EM structure of CtBP2 confirms tetrameric architecture.

Authors:  Anne M Jecrois; M Michael Dcona; Xiaoyan Deng; Dipankar Bandyopadhyay; Steven R Grossman; Celia A Schiffer; William E Royer
Journal:  Structure       Date:  2020-12-01       Impact factor: 5.871

7.  C-terminal of E1A binding protein 1 enhances the migration of gastric epithelial cells and has a clinicopathologic significance in human gastric carcinoma.

Authors:  Can Wang; Min Wang; Bocheng Xing; Zhaocheng Chi; Hongyu Wang; Chunxiao Lie; Han Dong
Journal:  Onco Targets Ther       Date:  2019-07-02       Impact factor: 4.147

8.  Correlation between microvessel density (MVD) and multi-spiral CT (MSCT) perfusion parameters of esophageal cancer lesions and the diagnostic value of combined CtBP2 and P16INK4A.

Authors:  Qinghua Li; Dong Cui; Yu Feng; Yanfei He; Zheng Shi; Rui Yang
Journal:  J Gastrointest Oncol       Date:  2021-06

9.  Inhibition of CtBP-Regulated Proinflammatory Gene Transcription Attenuates Psoriatic Skin Inflammation.

Authors:  Hong Li; Caiguo Zhang; Li Bian; Hui Deng; Melanie Blevins; Gangwen Han; Bin Fan; Chunxia Yang; Rui Zhao; Whitney High; David Norris; Mayumi Fujita; Xiao-Jing Wang; Mingxia Huang
Journal:  J Invest Dermatol       Date:  2021-07-20       Impact factor: 8.551

Review 10.  The transrepression and transactivation roles of CtBPs in the pathogenesis of different diseases.

Authors:  Zhi Chen
Journal:  J Mol Med (Berl)       Date:  2021-07-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.